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Objectives -To compare the antibiotic susceptibility of Pseudomonas aeruginosa strains with increased 24 efflux-pump expression in vitro and in vivo and to use these same strains to evaluate the efficacy of 25 combinations of antibiotics with putative efflux-pump inhibitors in vivo. 26
Methods -A collection of P. aeruginosa strains that over-express three efflux-pumps (MexAB-OprM, 27
MexCD-OprJ, MexEF-OprN), in addition to a strain with all three Mex pumps deleted, were used. The 28 virulence of these strains and their antibiotic susceptibility was measured in vivo using a Galleria mellonella 29 larval infection model. The inhibitory effect of combinations of putative efflux-pump inhibitors (trimethoprim 30 and sertraline) with antibiotics on the strain over-expressing MexAB-OprM was also measured in vitro and 31 compared with their efficacy in vivo in terms of larval survival and bacterial burden. 32
Results -Increased expression of the individual efflux-pumps, or deletion of all three, had no significant 33
Introduction
Pseudomonas aeruginosa is a ubiquitous, opportunistic pathogen prominent in hospitalised, 50 immunocompromised patients where it targets the urinary and respiratory tracts, kidneys and bloodstream 51 principally via invasive fomites such as catheters and mechanical ventilators. 1 Treatment of P. aeruginosa 52 infections can be difficult due to its high intrinsic resistance, which in turn has been amplified by the rapid 53 spread of resistance determinants and arrival of the MDR phenotype where isolates are resistant to three 54 or more different classes of antibiotics. 55
The over-expression of membrane-associated efflux-pumps that contribute to reduced efficacy of a number 56 of important classes of antibiotics used against P. aeruginosa is an important contributor to resistance. 2 
57
The most significant family of efflux-pumps that mediate antibiotic resistance in P. aeruginosa are those 58 belonging to the resistance-nodulation-division (RND). Four of the twelve member RND family are strongly 59 associated with antibiotic efflux: MexAB-OprM, MexXY-OprM, MexCD-OprJ and MexEF-OprN. 3 These four 60 pumps transport an overlapping range of antibiotic substrates, in particular the fluoroquinolones. However, 61
MexAB-OprM is the least discriminatory, with a broad substrate range allowing extrusion of almost all 62 classes of antibiotic, and is the most important efflux-pump mediating antibiotic resistance because it is 63 constitutively expressed and responsible for much of the intrinsic resistance of the organism. 3 Knockout of 64 mexAB-oprM results in hyper-susceptibility to antibiotics. 4 In contrast, expression of MexCD-OprJ and 65
MexEF-OprN requires exposure to a broad range of compounds or environmental stimuli.
2 MexCD-OprJ's 66 substrate range mirrors that of MexAB-OprM while MexEF-OprN appears the least versatile. 3 Knockout of 67 either of these two pumps does not affect antibiotic susceptibility. 5 Mutations in efflux-pump regulatory 68 from these bacteria. Using a collection of characterised P. aeruginosa strains that over-express three RNDmeropenem. Each EPI was screened in combination with the antibiotics at concentrations over three ordersof magnitude that were lower than the MIC values for each EPI. Microplates were incubated at 37ºC and 107 the MIC was defined as the concentration present in the first optically clear well after 24 h. Each experiment 108 was performed in triplicate. Fractional inhibitory concentration index (FICI) values were calculated for each 109 combination tested, 14 and synergy was defined as FICI ≤0.5. 110
G. mellonella model of P. aeruginosa infection and determination of G. mellonella haemolymph burden. 111
This was performed exactly as previously described. 13 Unless otherwise stated, groups of larvae were 112 infected with an inoculum of of 2.5x10 3 cfu/mL of P. aeruginosa cells. For experiments involving a single 113 dose of levofloxacin (0.2, 1 or 5 mg/kg), piperacillin (10, 25 or 100 mg/kg) or meropenem (0.1, 0.25 or 0.5 114 mg/kg), the antibiotics were administered 2 h post-infection (p.i). For experiments involving triple doses of 115 either single drugs or dual drug combinations, 1 and 5 mg/kg levofloxacin were used for PAM1020 and 116 PAM1032, respectively. A dose of 100 mg/kg of either trimethoprim or sertraline was used in combination 117 with levofloxacin as pilot studies using both PAM1020 and PAM 1032 revealed this dose resulted in optimal 118 results (data not shown). Triple doses were administered 2, 4 and 6 h p.i. Each experiment used groups 119 containing 15 larvae and experiments were performed twice using larvae from different batches. The data 120 from these replicate experiments were pooled to give n=30. Survival data were plotted using the Kaplan-121
Meier method and comparisons made between groups using the log rank test. In all comparisons to the 122 negative control it was the uninfected control (rather than the unmanipulated control) that was used. In all 123 tests P0.05 was considered significant and Holm's correction was always applied to account for multiple 124 comparisons. 15 
125
For haemolymph burden, groups of 30 larvae were infected with 2.5x10 3 cfu/mL of P. aeruginosa. As 126 above, single drug or dual combinations were administered at either 2 h p.i. as a single dose or at 2, 4 and 127 6 h p.i. for multiple dosing. The larvae were incubated in Petri dishes at 37ºC. At 24 h intervals, five larvae 128 were selected at random from each treatment group and tested for haemolymph burden exactly as 129 previously described. 16 killed P. aeruginosa inoculum (inoculation dose of 2.5x10 8 cfu/mL) had no significant detrimental effect on 135 larval survival (P>0.05) indicating that infection with live bacteria is required to cause larval death. 136
Inoculation with 25 cfu/larva of each strain resulted in 100% lethality after 24 h compared to controls sham-137 infected with PBS. No difference in virulence between the strains was discernible. Reducing the inoculum 138 size 10-fold to 2.5 cfu/larva allowed better discrimination of any differences in virulence between the 139 strains. Despite some apparent differences in larval survival 48 h post-infection (p.i), after 96 h there was 140 no significant difference (P≥0.05) in survival of larvae infected with any of the strains tested. In conclusion, 141 alteration of efflux-pump expression had no significant effect on the virulence of P. aeruginosa in G. Pseudomonal antibiotics is shown in Table 2 . Over-expression of mexAB-oprM (PAM1032) conferred 148 resistance to ceftazidime, piperacillin, meropenem and levofloxacin compared to the isogenic parent 149 (PAM1020). Over-expression of mexCD-oprJ (PAM1033) and mexEF-oprN (PAM1034) conferred 150 significant resistance to levofloxacin only. The mutant with all three efflux pumps deleted (PAM1626) 151 displayed susceptibility to ceftazidime, piperacillin, meropenem and levofloxacin compared to the parent 152 (PAM1020). Together, these results are consistent with many previous studies on the substrate specificity 153 of these efflux-pumps. 
154
To study the effect of altered efflux pump expression on in vivo antibiotic efficacy infected larvae were 155 treated with levofloxacin, piperacillin and meropenem as these three drugs had the largest differences in 156 susceptibility between the mutant and parent strains in vitro (see Table 2 ). Larvae were infected with each 157 strain of P. aeruginosa and the effect of a single, increasing dose of each antibiotic on survival measured 158 ( Figure 1 ). Treatment with 0.2 mg/kg of levofloxacin conferred no therapeutic benefit on larvae infected with 159 any of the P. aeruginosa strains tested. Notably, a single dose of 1 mg/kg levofloxacin only inducedtriple deletion mutant but also the parent strain (PAM1020). Notably, this highest dose of levofloxacinoffered no therapeutic benefit to larvae infected with the three mutant strains that over-expressed the three 164 efflux pumps (PAM1032, PAM1033 and PAM1034). A similar trend of antibiotic efficacy, dependent on the 165 level of efflux-pump expression, was also observed when larvae infected with each strain were treated with 166 increasing doses of piperacillin. Similar to treatment with levofloxacin and piperacillin, treatment with 167 meropenem was most effective on larvae infected with the mutant with all three efflux pumps deleted 168 (PAM1626). Treatment with 0.25 or 0.5 mg/kg meropenem proved to be efficacious to larvae infected with 169 the parent strain (PAM1020) and the strains over-expressing mexCD-oprJ (PAM1033) or mexEF-oprN 170 (PAM1034). Notably, over-expression of mexAB-oprM (PAM1032) abolished this efficacy. 171
In conclusion, the expression level of efflux-pumps clearly influences antibiotic efficacy in vivo. 172
Furthermore, the in vivo efficacy of levofloxacin, piperacillin and meropenem versus larvae infected with P. 173 aeruginosa strains displaying altered expression of efflux-pumps reflected exactly the degree of 174 susceptibility to the same drugs that was measured in vitro. Table 1 . Only the mutant with all three efflux-pumps deleted (PAM1626) displayed any 182 substantial susceptibility, and the three strains over-expressing individual efflux pumps had a higher MIC 183 for trimethoprim than the parent, implying that all three putative EPIs may be substrates of these Mex 184 efflux-pumps. MIC and FICI values of the three EPIs in combination with levofloxacin, piperacillin and 185 meropenem are shown in Table 3 . Combination MICs were determined for the parent strain (PAM1020), 186 the triple efflux-pump deletion (PAM1626) and the mutant over-expressing mexAB-oprM (PAM1032). 187 PAM1032 was included over the mutants over-expressing mexCD-oprJ and mexEF-oprN because this 188 strain was the most resistant to levofloxacin, piperacillin and meropenem treatment in vivo and MexAB-189 oprM is responsible for intrinsic resistance of P. aeruginosa to many antibiotics. Combination ofversus the parent strain (PAM1020). The calculated FICI values for each of these combinations indicatedsynergistic inhibition (≤0.5). Synergy was also observed against the parent strain for combinations of 193 piperacillin with trimethoprim and PAβN, and meropenem with sertraline. None of the putative EPI/antibiotic 194 combinations showed significant synergy versus the strain with all three efflux-pumps deleted (PAM1626). over the 96 h duration of the experiment. Notably, the enhanced therapeutic benefit conferred by treatment 211 with the combinations was observed for infections with either the parent (PAM1020) or the strain over-212 expressing mexAB-oprM (PAM1032). This is in contrast to the results seen in vitro where neither of the 213 combinations was observed to be synergistic when tested against the mexAB-oprM over-expressing strain. 214
Comparison of the effect of triple doses of levofloxacin + trimethoprim or levofloxacin + sertraline with the 215 constituent monotherapies on the larval burden of the parent strain (PAM 1020) is shown in Figure 3 . Larval 216 burden following three doses of PBS increased from below the level of detection (≤ 2 log 10 cfu/mL) 5 h post-217 infection to greater than 9 log 10 cfu/mL after 24 h at 37ºC. Treatment with three doses of trimethoprimcorrelated with death of the larval population (Figure 2 
population increased to approximately 10 log 10 cfu/mL and the larval population died (Figure 2 ). Treatment 223 with triple doses of levofloxacin + trimethoprim or levofloxacin + sertraline completely eradicated bacterial 224 growth in infected larvae with detected numbers remaining below the level of detection (≤ 2 log 10 cfu/mL) in 225 most cases and this was reflected in the high levels of larval survival observed (Figure 2) . In summary, the 226 therapeutic benefit arising from treatment with efflux-pump inhibitor/antibiotic combination treatments 227 correlates with reduced larval burden of infecting P. aeruginosa. 228
To determine if the enhanced therapeutic benefit arising from treatment with efflux-pump inhibitor/antibiotic 229 combination treatments was also evident versus an infection by a different MDR strain an experiment was 230 performed using P. aeruginosa NCTC13437 12 (Table 1) . Importantly, treatment with triple doses of 231 levofloxacin + trimethoprim or levofloxacin + sertraline again resulted in significant increases in survival of 232 larvae infected with this strain compared to treatment with any of the constituent monotherapies over the 96 233 h duration of the experiment (Supplementary Figure 2) . 234
235

Discussion 236
Strains of P. aeruginosa harbouring mutations that result in the over-expression of efflux-pumps are 237 frequently isolated in the clinical setting. Invariably, these strains result in antibiotic treatment complications, 238 or failure, due to their antibiotic-resistant phenotype. 18, 19 This study has demonstrated that P. aeruginosa 239 strains that over-express efflux-pumps also result in the failure of antibiotic treatment in G. mellonella 240 larvae. The similarity between the antibiotic-resistant phenotypes of strains in the invertebrate infection 241 model and human patients shows that G. mellonella larvae represent a highly effective tool to develop and 242 evaluate novel treatment options to target clinical MDR strains of P. aeruginosa. 243
Piddock et al. 9 and Bohnert et al. 10 presented evidence from in vitro studies that trimethoprim and sertraline 244 both possessed EPI-like properties. Trimethoprim has been shown to be a substrate of the Mex pumps, in 245 particular MexAB-OprM 20 , and this explains the high levels of resistance measured in the over-expressing 246 strains and the apparent susceptibility of the strain with all three Mex pumps deleted in this worktrimethoprim or sertraline that were synergistic versus the P. aeruginosa parent strain did not show synergywhen applied to the strain with three efflux-pumps deleted supporting the previous conclusion that the two 250 drugs do have EPI activity. 251
The present work has presented in vivo evidence that antibiotic and trimethoprim (or sertraline) 252 combinations represent a potential treatment option for P. aeruginosa infections. Administration of 253 combinations of trimethoprim or sertraline with levofloxacin conferred significant therapeutic benefit in vivo 254 to infected G. mellonella larvae compared to those treated with the individual monotherapies. Importantly, 255 the enhanced therapeutic effect of these combinations in vivo was demonstrated against a MDR strain of P. 256 aeruginosa that over-expresses the MexAB-OprM efflux-pump. In terms of clinical relevance, the doses of 257 levofloxacin (1-5 mg/kg) employed in this study are comparable to those used in humans -approximately 8 258 mg/kg. 13 For human therapy, trimethoprim is usually administered in combination with sulfamethoxazole 259 with trimethoprim at 20 mg/kg. 21 This is lower than the dose of trimethoprim (100 mg/kg) in the successful 260 combination reported here and further studies will be needed to determine if it is feasible to employ this 261 higher dose of trimethoprim clinically. Furthermore, Bohnert et al. 10 have already stated that sertraline is 262 unlikely to be successful in combination treatments as the peak plasma levels attained are below the 263 concentrations that are required to inhibit efflux. 264
It is notable that combinations of both trimethoprim and sertraline with levofloxacin were not synergistic 265 versus the strain over-expressing the MexAB-OprM efflux-pump in vitro but resulted in significant 266 therapeutic benefit when tested in vivo. Similarly, combinations of PAβN with levofloxacin were synergistic 267 in vitro but conferred no therapeutic advantage over monotherapies when administered in vivo (data not 268 shown). These discrepancies between results obtained in vitro with those observed in vivo concur with 269 previous observations evaluating the efficacy of antibiotic only combination therapies carried out in the 270 corresponding author's lab. 16 In fact, there are examples in the literature where synergy between two 271 antibiotics observed in vitro does not translate into enhanced therapeutic benefit in patients. 22 The 272 implication of this is that by employing traditional in vitro methods to screen for effective combination 273 treatments (or novel antimicrobials per se) researchers could actually be discarding potential treatments 274 that are efficacious in vivo. Thus, screening in vivo using G. mellonella may be a better predictor of the 275 efficacy of novel treatments in patients than in vitro assays. To evaluate this possibility, studies are needed 276 urgently that compare the relative efficacy of established and novel treatments on infections in G.
outcomes
G. mellonella and mice 23 but there are few published studies comparing antibiotic efficacy in G. mellonella 281 with murine, or human, infections. Clearly, any effects identified in G. mellonella may not be relevant to 282 other mammalian infection models or humans. In addition to the obvious differences in the immune system 283 of invertebrates and mammals, the efficacy of some antimicrobial drugs versus infected G. mellonella has 284 been attributed not just to direct inhibition of the pathogen but also to activation, or priming, of the larval 285 innate immune response.
24 Additional experimentation will be required to determine if the efficacy of the 286 combination treatments reported here is relevant in mammals. 287
In summary, antibiotic-resistant strains of P. aeruginosa that over-express drug efflux-pumps and result in 288 treatment failure in human patients also result in the failure of antibiotic treatment in G. mellonella larvae. 289
Furthermore, combination treatments consisting of the putative EPIs, trimethoprim and sertraline, with 290 levofloxacin were significantly more efficacious than the individual monotherapies. The enhanced efficacy 291 of these combinations versus infected G. mellonella was evident against a MDR strain of P. aeruginosa that 292 over-expresses the MexAB-OprM efflux-pump, confirming that combinations of antibiotics with EPIs are a 293 potential treatment option for real infections with MDR P. aeruginosa. This study has also highlighted 294 discrepancies in results obtained from in vitro and in vivo antimicrobial testing that could mean false 295 positives are inadvertently selected and novel treatment options missed. Together, these findings further 296 demonstrate the utility of using G. mellonella to develop and evaluate novel treatment options to target 297 clinical MDR strains of P. aeruginosa. 298
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